Novartis Ag · SIX:NOVN
Novartis — 9M 2001 Earnings Presentation
12 slides from Novartis's earnings presentation, October 2001
Slide 1: Nine Months 2001 Sales Background Information
Nine Months 2001 Sales Background Information Investor Relations October 2001
Slide 2: Growth Components by Sector
Nine Months 2001 Sales Growth Components by Sector Volume Price Acq./Div. Currency Pharmaceuticals + 11 % +2% +2% -3% Generics +8% -6% + 18 % -2% Consumer Health +4% +1% +0 % -1% CIBA Vision +6% -2% + 42 % -4% Animal Health -6% 0% 0% -3% Group +8% +1% +4% -2% 2 n
Slide 3: Third Quarter 2001 Sales Growth by Sector
Third Quarter 2001 Sales Growth by Sector Q3 2001 Q3 2000 Change USD m CHF m CHF m in CHF % in LC % Pharmaceuticals 3214 5207 46261 13 17 Generics 393 636 4731 34 38 Consumer Health 1029 1667 16121 3 6 CIBA Vision 299 485 3431 41 48 Animal Health 139 225 275 -18 -13 Group 5074 8220 7329 12 16 3 1 Re
Slide 4: Pharmaceuticals Top 20 Products I Total Sales Growth
Pharmaceuticals Top 20 Products I Total Sales Growth Brands Total 9 month Sales % Change 2001 USD m CHF m in CHF in LC Sandimmun®/Neoral® 856 1387 -11 -8 Diovan®/Co-Diovan® 819 1327 56 58 Cibacen®/Lotensin® 699 1133 29 27 of which Lotrel® 364 589 57 55 Lamisil® 659 1068 16 19 Aredia® 611 990 21 22 V
Slide 5: Pharmaceuticals Top 20 Products II Total Sales Growth
Pharmaceuticals Top 20 Products II Total Sales Growth Brands Total 9 month Sales % Changes 2001 USD m CHF m in CHF in LC Leponex®/Clozaril® 248 402 -11 -10 Estraderm® (group) 225 364 5 6 Exelon® 193 312 152 154 Foradil® 175 283 15 17 Visudyne® 170 276 168 168 Famvir® /Denavir® 167 270 na na Nitroder
Slide 6: Sales Performance of Recently Launched Pharmaceutical Products
Sales Performance of Recently Launched Pharmaceutical Products 9 months in CHF m Comtan® 98 Femara® 147 Gleevec™ 140 Starlix® 55 Trileptal® 170 Zometa® 24 6 n
Slide 7: Pharmaceuticals Top 20 Products I US Sales Growth
Pharmaceuticals Top 20 Products I US Sales Growth Brands US 9 months Sales 2001 USD m CHF m % Change LC Sandimmun®/Neoral® 250 405 -21 Diovan®/Co-Diovan® 412 667 44 Cibacen®/Lotensin® 601 974 36 of which Lotrel® 364 589 55 Lamisil® 347 562 21 Aredia® 399 647 23 Voltaren® 13 21 -61 Sandostatin® 163 2
Slide 8: Pharmaceuticals Top 20 Products II US Sales Growth
Pharmaceuticals Top 20 Products II US Sales Growth Brands US 9 months Sales 2001 USD m CHF m % Change LC Leponex®/Clozaril® 107 174 -23 Estraderm® (group) 102 166 30 Exelon® 107 173 307 Foradil® 4 7 na Visudyne® 109 177 153 Famvir® /Denavir® 116 188 na Nitroderm TTS® 0 0 -90 Zaditen® na na na Trilep
Slide 9: Pharmaceuticals Top 20 Products I RoW Sales Growth
Pharmaceuticals Top 20 Products I RoW Sales Growth Brands RoW 9 month sales 2001 USD m CHF m % Change LC Sandimmun®/Neoral® 606 982 -3 Diovan®/Co-Diovan® 407 660 75 Cibacen®/Lotensin® 98 159 -7 of which Lotrel® na na na Lamisil® 312 506 16 Aredia® 212 343 20 Voltaren® 482 781 -7 Sandostatin® 218 354
Slide 10: Pharmaceuticals Top 20 Products II RoW Sales Growth
Pharmaceuticals Top 20 Products II RoW Sales Growth Brands RoW 9 month Sales 2001 USD m CHF m % Change LC Leponex®/Clozaril® 141 228 3 Estraderm® (group) 123 198 -7 Exelon® 86 139 77 Foradil® 171 276 15 Visudyne® 61 99 198 Famvir® /Denavir® 51 82 na Nitroderm TTS® 147 238 -3 Zaditen® 123 200 -7 Tril
Slide 11: Pharmaceuticals Top 20 Products I Market Segments
Pharmaceuticals Top 20 Products I Brands Market segment Sandimmun®/Neoral® Transpl., RA, Psoriasis Diovan®/Co-Diovan® Hypertension Cibacen®/Lotensin® Antihypertensives Aredia® Oncology (Bone) Lamisil® Fungal infections Voltaren® Antirheumatics Sandostatin® Acromegaly Miacalcic® Osteoporosis Lescol®
Slide 12: Pharmaceuticals Top 20 Products II Market Segments
Pharmaceuticals Top 20 Products II Brands Market segment Leponex®/Clozaril® Schizophrenia Exelon® Alzheimer’s disease Estraderm® Hormone replacement Foradil® Asthma, Bronchitis Famvir® Antivirals Visudyne® A form of wet AMD Nitroderm TTS® Heart disease Zaditen® Asthma, Allergy Parlodel® Parkinson’s